Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
about
Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectivesMetabolic syndrome and its components in patients with psoriasis.Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies.Increased prevalence of the metabolic syndrome in patients with psoriatic arthritisPsoriatic arthritis and diabetes: a population-based cross-sectional studyPsoriasis comorbidities: complications and benefits of immunobiological treatmentEfficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasisComorbidities in Patients with Psoriatic Arthritis.The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.Alternative macrophage activation and metabolism.Mood disorders and obesity: understanding inflammation as a pathophysiological nexus.Obesity and the skin.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies.Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?Subclinical cardiovascular disease and it's improvement after long-term TNF-α inhibitor therapy in severe psoriatic patients.Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study.Risk of myocardial infarction in psoriasis patients: a retrospective cohort study.Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis.Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab).A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis.The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis.Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis
P2860
Q34060084-3EA8B8E8-4DC1-4A41-8BBE-67A65D23ABC8Q34409690-30EF4285-4D0C-4A20-B696-A3C033B1DAB4Q34444895-0C591419-53ED-47BF-BF3B-5B0AC2137F0CQ35036116-99D49D65-732B-4EE8-BB26-FA909DAA479AQ35086458-972A585B-4A0B-48B8-B1FC-69024C99887FQ36988417-5DFA9175-211B-43C8-BCAF-AACE7F0109AAQ37540440-ADF03284-5EF6-44C1-AE27-1D623B0720FFQ37592632-9BE5BD38-A56C-4EA8-9C7C-46C89FF7D764Q37632137-40DDD6B6-F605-48C5-9522-29C29C5A10CCQ37766229-796DCA8F-DB5E-4DBD-A68B-7B1C38166382Q37804862-F8A78A17-9679-4211-9918-C8A4E7DBEE19Q37821806-C1F5F8B1-8775-439D-B402-834FE68DC4CCQ37874647-FC61D181-EC92-4F94-8652-B3A921F812D2Q38099248-0F7AB214-7A41-45EB-8644-2E579BCD70CBQ38181566-2B0A8516-15FF-4C9B-8D5D-514CFF7C382EQ38845570-071F99B6-3AA8-4AF3-9791-49D453E48645Q39620045-40E1EF7A-3E0C-43FA-95ED-65A65F190CD7Q42640551-43A0A41E-475A-4473-A420-FCE99E818E5BQ45077865-7E436E1D-DC36-448D-8AE3-276C5A13FEB9Q46048754-C26424F1-C504-48C2-9097-6EF932D59CEBQ46286636-2FD7D3E0-DDF8-4A94-A2E9-E8409763AFAFQ48239956-CE5F17D2-1E8B-4F73-8498-8F9944C4FB4AQ51323473-DAD1F9D3-B2D9-45B7-AA3E-34517059CF4BQ51350319-9B06686B-2B8E-4127-82E4-5A974CD27626Q54619049-150666F8-88FC-4FD5-A298-22930B0F4425Q59036140-D0C20B1F-831F-4626-9AB1-781D49EDC108
P2860
Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@en
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@nl
type
label
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@en
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@nl
prefLabel
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@en
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@nl
P2860
P1433
P1476
Effects of tumor necrosis fact ...... ned from rheumatoid arthritis.
@en
P2093
Frank J Dann
Jennifer Channual
P2860
P356
10.1111/J.1529-8019.2008.01217.X
P50
P577
2009-01-01T00:00:00Z